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The cardiovascular disease (CVD) epidemic remains the
leading cause of death worldwide (1). Widespread adoption
of the Western diet and lifestyle by populations in emergent
countries with low or middle income has resulted in
dramatic increases in the incidence of coronary heart disease
and stroke. An overwhelming proportion of the cardiovas-
cular risk is explained by the cumulative presence of classic
and potentially modiﬁable risk factors, and this effect does
not seem to be inﬂuenced by sex, ethnicity, or geography (2).See page 434Therefore, to effectively reduce risk and improve outcomes,
prevention strategies should be conducted and implemented
at the population level. Yet in 2003, Wald and Law (3)
introduced the concept of preventive pharmacotherapy as
an attractive, but controversial, weapon to beat the CVD
epidemic. According to most optimistic calculations, the
implementation of a strategy based on preventive pharma-
cotherapy in subjects age 55 years, without known but
at moderate risk of CVD, would result in 60% to 90%
reduction in coronary heart disease events and 48% to 80%
reduction in stroke rates (4,5). Unfortunately, hard data on
the actual risk reduction that is associated with preventive
pharmacotherapy using the polypill are presently still lacking.
In this issue of the Journal, Bittencourt et al. (6) propose
an interesting novel approach to preventive pharmaco-
therapy to potentially improve its effectiveness. Using the
coronary artery calcium (CAC) score, the authors enrich the
population amenable to polypill treatment by selecting
a higher-risk subset with subclinical disease present.*Editorials published in the Journal of the American College of Cardiology reﬂect the
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paper to disclose.Applying “what-if” calculations, the authors report the
impact of adding CACS to the actual inclusion criteria for
polypill studies. Participants of MESA (Multi-Ethnic Study
of Atherosclerosis) who fulﬁlled the inclusion criteria of 4
published polypill trials were stratiﬁed according to baseline
CAC score and CVD events during a 7.6-year median
follow-up were compared. The results of this analysis are of
great interest and can be brieﬂy summarized as follows:
1) the rate of CVD events is low for patients with CAC ¼ 0
(2.5 to 4.0 per 1,000 person-years), whereas patients with
CAC >100 experience most of the CVD events (15.8 to
18.6 per 1,000 person-years); 2) assuming a 62% reduction
of CVD events with preventive pharmacotherapy, the esti-
mated 5-year number needed to treat (NNT) to prevent
1 CVD event ranges between 84 and 134 for the group
with CAC ¼ 0 and decreases dramatically to only 20 in
patients with CAC >100; 3) the estimated NNT is still
acceptable for the group with CAC >100 in case the antic-
ipated risk reduction would be less than 62% (sensitivity
analysis); and 4) CAC classiﬁcation provides good discrim-
ination in the NNT to prevent CVD events across the whole
spectrum of the Framingham risk score. These ﬁndings
suggest that a simple and rather inexpensive imaging method
identiﬁes patients who might beneﬁt the most from pre-
ventive pharmacotherapy. The approach proposed by the
authors is probably also cost effective because pharmaco-
therapy is deferred in low-risk individuals with CAC ¼ 0,
who represent 40% to 60% of subjects in the published pol-
ypill studies. Presumably, these subjects would no longer
be exposed to potential side effects of the polypill, while
no beneﬁt was to be expected anyhow.
The following aspects of the proposed strategy deserve
further comments. 1) What is the predictive value of CAC
in asymptomatic individuals with different risk proﬁles
drafted from the general population? 2) Will CAC ever be
available and affordable at large to be applicable on a pop-
ulation basis? 3) Preventive pharmacotherapy with the pol-
ypilldare we even prepared to implement it?
In the assessment of cardiovascular risk, CAC is
currently considered a Class IIa recommendation for
asymptomatic individuals at intermediate risk (10% to 20%
10-year risk) and a Class IIb recommendation for low- to
intermediate-risk persons (6% to 10% 10-year risk) (7).
CAC improves Framingham CVD risk prediction through
signiﬁcant reclassiﬁcation of subjects between risk cate-
gories. When added to a prediction model based on tradi-
tional risk factors, CAC results in reclassiﬁcation of 26%
of patients and 25% of events (8). Among individuals with
intermediate 10-year risk, CAC permits reclassiﬁcation of
16% as high risk and 39% as low risk (8). Overall, adding
CAC to a classic estimation of risk places almost 80% of
the population into either the highest or the lowest category
of risk (8). Thus, CAC incrementally improves risk esti-
mates in individual subjects, above and beyond the predic-
tive power of clinical scores that are most effective at
a population level.
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445Bittencourt et al. (6) show that adding CAC to the
traditional classiﬁcation of risk by Framingham score
translates into higher visibility of individuals in whom
pharmacological prevention would be most effective. CAC
shows signiﬁcant discrimination in the NNT to prevent
events across the whole spectrum of traditional risk cate-
gories. Irrespective of Framingham risk, NNT to prevent
coronary heart disease events is highest for CAC ¼ 0
(between 135 and 162 in intermediate-risk individuals and
between 68 and 126 in high-risk individuals). On the
contrary, when CAC is >100, NNT to prevent coronary
heart disease events is small even in low-risk individuals
(between 38 and 56). These data suggest that a CAC-based
risk strategy can guide preventive measures through better
visibility of subjects having the disease substrate and who
represent the actual target for risk reduction (9). Given the
poor performance of classic risk scores at the individual
level, the design of future trials in this ﬁeld should consider
using CAC in addition to risk scores to focus preventive
pharmacotherapy on individuals most likely to beneﬁt. This
“de-risking” approach to risk reduction could be coined
“interventional prevention.”
The availability of imaging centers in emerging countries
and remote areas is a real issue that might limit the imple-
mentation of a CAC-based preventive pharmacotherapy
strategy. One should also keep in mind that about one-
quarter of individuals with CAC ¼ 0 show some amount of
coronary calciﬁcation 5 years later (10). This opens the
discussion of serial CAC assessment and complicates the
delivery of preventive pharmacotherapy beyond 5 years. On
the other hand, the absence of coronary calciﬁcations in low-
risk patients is strongly correlated to absence of obstructive
coronary lesions but does not exclude the presence of non-
obstructive coronary heart disease in short of 10% of cases.
With modern equipment, the effective radiation dose per
CAC study is low, ranging between 0.7 and 1.3mSv, which is
still much higher than the effective radiation dose of a chest
x-ray study (about 0.02 mSv) and might be associated
with incremental risk of cancer. Lastly, CAC screening with
abnormal results in otherwise healthy subjects may trigger
unnecessary additional noninvasive or invasive examinations,
leading to greater expenditures for healthcare systems.
To date, all studies investigating preventive pharmaco-
logical strategies at the population level have used surrogate
endpoints to evaluate CVD risk reduction. The recently
published UMPIRE (Use of a Multi-Drug Pill in Reducing
Cardiovascular Events) trial randomized 2004 subjects with
established CVD (history of coronary heart disease, ischemic
cerebrovascular disease, or peripheral artery disease) or with
an estimated 5-year CVD risk of 15% or greater to a single
ﬁxed-dose polypill or with usual care (11). The trial showed
that a ﬁxed-dose combination strategy resulted in better
control of blood pressure and low-density lipoprotein
cholesterol and improved adherence at 15 months as
compared with usual care; granted, these are patients with
known disease (11). The ongoing large international HOPE(Heart Outcomes Prevention Evaluation)-3 trial is investi-
gating the effect of a combined therapy (statin, angiotensin
receptor antagonist, and thiazide diuretic) on CVD events in
12,500 individuals without known heart disease at average
risk (12). This trial is aimed at providing robust evidence
supporting more widespread application of preventive
pharmacotherapy. Until then, many healthcare providers are
uncertain about its value and seem reluctant to prescribe the
polypill for primary prevention in individuals at low or
intermediate risk, for a number of reasons (13). The ideal
composition of the polypill and the best dosage to avoid
adverse effects and drug interactions remain subjects of
debate. This is of importance because adverse effects nega-
tively impact compliance and adherence to therapy. One
may fear that healthy adults at moderate risk endure side
effects that limit physical performance and interfere with
personal and professional activities for the sake of preven-
tion. Data from the PILL Collaborative Group (14) show
that the polypill arm had signiﬁcantly more adverse effects
than the placebo group and that roughly 1 out of 20
participants stopped medication because of such effects.
Others are concerned that the development of preventive
pharmacotherapy might undermine the achievements of
preventive medicine with respect to the implementation of
indispensable lifestyle-modiﬁcation measures, especially
smoking cessation, weight reduction, and physical exercise.
Technological and medical progress must not lead to an
inert society where individuals assess periodically their risk,
pursue unhealthy habits, and take medication to reassure
themselves or to please their physicians.
Despite, or perhaps because of, these potential short-
comings, reﬁning risk prediction by adding CAC to classic
scores as proposed by Bittencourt et al. (6) is an innovative
approach to preventive strategies. Unlike implementation
of healthy diet and lifestyle modiﬁcation, preventive phar-
macotherapy in asymptomatic healthy subjects remains
controversial. Because long-term drug prescription un-
avoidably comes with side effects, it is conceivable that the
potential beneﬁt of polypill prescription will be confounded.
As a result, polypill trials may run the risk of showing
neutral or even negative net effects. Using CAC to identify
subjects at intermediate to high risk who carry the disease
substrate at a pre-clinical state for inclusion in such trials
seems like an attractive “de-risking” strategy for preventive
pharmacotherapy.Reprint requests and correspondence: Dr. William Wijns,
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